With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1072027-36-1,4-(4-Boc-1-piperazinyl)-5-bromo-7H-pyrrolo[2,3-d]pyrimidine,as a common compound, the synthetic route is as follows.
Description 16; 1,1 -Dimethylethyl 4-{5-bromo-7-[2-(ethyloxy)-2-oxoethyl]-7H-pyrrolo[2,3- d]pyrimidin-4-yl}-1 -piperazinecarboxylate (D16)1 ,1-Dimethylethyl 4-(5-bromo-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1- piperazinecarboxylate (D15, 552 mg, 1.444 mmol) was dissolved in N, N- dimethylformamide (14 ml_), cooled in an ice bath and treated with sodium hydride (60% by weight, 69.3 mg, 1.733 mmol) portionwise and stirred under argon for 15 minutes. The reaction mixture was allowed to warm to room temperature and stirred for 1 hour. Ethyl bromoacetate (0.160 ml_, 1.444 mmol) was added and the resulting mixture stirred for 1 hour. The solvent was removed under reduced pressure. The residue taken up in water, neutralised using saturated ammonium chloride and extracted with ethyl acetate (x 3). The ethyl acetate layers were combined, dried under magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography eluting with a gradient of 0-50 % ethyl acetate/iso-hexane. Product containing fractions were combined and evaporated under reduced pressure to give the title compound as a white solid. LC/MS (ES+ve): [M+H]+ at m/z 468, 470 (Ci9H26BrN5O4 requires [M+H]+ at m/z 468, 470).
1072027-36-1, As the paragraph descriping shows that 1072027-36-1 is playing an increasingly important role.
Reference：
Patent; GLAXO GROUP LIMITED; WO2009/80682; (2009); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics